Emory Healthcare, a leading academic health system, has formed a strategic partnership with Atropos Health to advance medication formulary decisions and protocols through real-world clinical data analysis. The collaboration aims to enhance patient care by enabling clinicians to answer critical questions in real time using Atropos' sophisticated data platforms.
The partnership centers on a pilot program that gives Emory users access to the Atropos Evidence Network, allowing them to conduct studies using both national datasets and local Emory data. Clinicians can leverage Atropos' Green Button technology to access real-world evidence through either supervised evidence development or a fully automated generative AI solution called ChatRWD.
ChatRWD represents a significant advancement in clinical research tools, functioning as a large language model (LLM)-powered chat platform that eliminates hallucination risks by utilizing the company's GENEVA OS real-world data platform.
Dr. Alistair Erskine, enterprise chief information and digital officer for Emory Healthcare and Emory University, highlighted the unique value of the partnership: "Atropos Health provides a means to answer questions not specifically or robustly answered in published data; Atropos surfaces practice-based evidence where evidence-based medicine does not exist."
The initiative is already demonstrating positive outcomes. "We are already seeing early success as one of our users explored real-world outcomes, adverse events and costs of a drug that will improve our drug therapy protocol and benefit Emory patients," Dr. Erskine added.
This partnership represents part of a broader expansion strategy for Atropos Health, which has established several significant collaborations in recent years. In January, the company partnered with xCures to develop AI-powered prognostic and decision-support tools for healthcare providers.
Additionally, Atropos formed a partnership with pharmaceutical company Merck to generate real-world evidence, replicate studies, and produce rapid insights from clinical data. The company's growth has been supported by substantial financial investment, including $33 million in Series B funding secured last year.
The company has also expanded its evidence network through partnerships with healthcare data analytics company Arcadia, providing Arcadia's customers with access to Atropos' clinical decision-making tools. In 2023, Atropos partnered with data-sharing technology platform Datavant, creating mutual access to each company's offerings, following a $14 million Series A funding round in 2022.
Click here for the original news story.